Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.320
-0.050 (-2.11%)
At close: Apr 28, 2026, 4:00 PM EDT
2.420
+0.100 (4.31%)
After-hours: Apr 28, 2026, 4:47 PM EDT

Galectin Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Selling, General & Admin
5.85.865.946.626.36
Upgrade
Research & Development
14.2936.5732.1331.7423.82
Upgrade
Operating Expenses
20.0942.4338.0738.3530.18
Upgrade
Operating Income
-20.09-42.43-38.07-38.35-30.18
Upgrade
Interest Expense
-7.33-5.54-2.79-1.03-0.49
Upgrade
Interest & Investment Income
0.130.340.230.050
Upgrade
Other Non Operating Income (Expenses)
-3.550.59-0.430.560.14
Upgrade
Pretax Income
-30.84-47.05-41.07-38.78-30.53
Upgrade
Net Income
-30.84-47.05-41.07-38.78-30.53
Upgrade
Preferred Dividends & Other Adjustments
0.140.153.740.10.17
Upgrade
Net Income to Common
-30.97-47.2-44.81-38.87-30.7
Upgrade
Shares Outstanding (Basic)
6462605959
Upgrade
Shares Outstanding (Diluted)
6462605959
Upgrade
Shares Change (YoY)
2.56%3.57%1.29%1.48%2.63%
Upgrade
EPS (Basic)
-0.48-0.76-0.74-0.65-0.52
Upgrade
EPS (Diluted)
-0.48-0.76-0.74-0.65-0.52
Upgrade
EBIT
-20.09-42.43-38.07-38.35-30.18
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.